Article 27 Notarised Undertaking and Red-Wax Sealing for Early Release

Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Yes, it exists. Article 27 of Public Health Law No. 89 of 1981 allows the Directorate of Public Health Prevention, as an exception, to let goods under laboratory testing leave customs custody before the health certificate is issued to their owners, provided three conditions are satisfied together: an undertaking not to dispose of the goods, authenticated by a notary; storage under the direct supervision of the competent authority; and red-wax sealing of the storage premises, until the laboratory result is issued. This is not an official’s case-by-case discretion but an alternative release mechanism written into statute. For companies, its significance is that Iraq’s detain–seal–release sequence has a complete legal parent, and any sealing demand going beyond these three conditions can be met with a request to cite the legal basis.

  • The three statutory conditions are a notarised no-disposal undertaking, storage under direct official supervision, and red-wax sealing of the storage place.
  • All three must be satisfied together and last until the laboratory result appears.
  • Early release exists only within the scope of Article 26 laboratory testing; it cannot be invoked freely.

2. Legal basis

Source level: primary source, verified. — https://faolex.fao.org/docs/pdf/irq149622.pdf

Public Health Law (Qanun al-Sihhah al-Ammah No. 89 of 1981, as amended)No. 89 (1981)Issued 1981-08-01; published in the Official Gazette of Iraq on 1981-08-17Article 27
Successive amendment laws (none touches Article 27)No. 53 (1986), No. 71 (1988), No. 54 (2001), No. 20 (2021)1986 / 1988 / 2001 / 2021See remarks column
Official gazette full text hosted by FAOLEXLEX-FAOC149622, marked as in forceVerification date 2026-10-29Article 27 wording checked, terms consistent

Excerpts of the provision:

  • Article 27 grants the Directorate of Public Health Prevention the power to approve, as an exception, the removal of goods subject to laboratory examination from customs custody before the health certificate is granted to their owners, against an undertaking not to dispose of them, authenticated by a notary, with the goods stored under the direct supervision of the competent authority and the storage place sealed with red wax, until the result of the laboratory examination appears.

3. Expert insights

Insight 1 | GRZAN has not seen a second example, across Middle East jurisdictions, of legislation written to the granularity of red wax. Most jurisdictions leave the handling of goods after sampling to customs operating rules or internal departmental guidance; what material the seal is made of and who applies it are execution-level details. Iraq wrote the form of the undertaking, the supervising body and the sealing method into Article 27 together, which amounts to setting statutory constitutive elements for early release. The direct effect is that the authority may say yes or no to a release, but once Article 27 applies, the entire sequence — notarised undertaking, officially supervised storage and red-wax sealing — must be carried out, and the procedure cannot be simplified.

Insight 2 | Notary authentication brings a third-party resource into the process. The notary belongs neither to the health system nor to customs. Requiring the undertaking to be authenticated by a notary means that a company applying for early release must mobilise an additional judicial-administrative resource, which lengthens processing time and generates extra cost. This also explains why early release is not used frequently in Iraqi practice — it is not a cost-free option. Practical estimate: companies should confirm in advance whether a notary channel able to act immediately exists at the importer’s location (no official provision found).

Insight 3 | Horizontal comparison: medicines have a legal parent provision; devices have no corresponding clause anywhere in this fully obtained code. Article 27 attaches to the scope of application of Article 26: only goods subject to laboratory examination under Article 26 can invoke it. Medicines and medical preparations fall clearly within the reach of Article 26 and therefore enjoy this statutory release channel; medical devices are not within the named scope of Article 26 (see article 41 of this series), so there is no question of invoking Article 27 to claim early release for them. This is a textbook example of scope propagating within a single law: a procedurally neutral clause is in fact available only to particular product categories.

Insight 4 | Falsification check: the claim that Iraq can release goods freely and that personal connections suffice to pick up detained cargo does not hold. The circulating story is that port operations in Iraq are highly flexible and that, with the right contacts, detained goods can be extracted. For the situations covered by Article 27, the law fixes the prerequisites: without a notarised undertaking, without a warehouse under official supervision, without red-wax sealing, early release has no textual basis. Conversely, if someone demands an expediting release fee on grounds outside Article 27, the company should require written legal authority — and if none is produced, treat the demand as unfounded.

Insight 5 | Article 27 conversely defines the lawful boundary of detention. The provision makes awaiting the laboratory result the terminal state of the early-release period, which shows that the legality of detention rests on the examination being in progress. If goods have been detained but never sent for testing, or the result was issued long ago while release is still withheld, that state has gone beyond the authorisation of Article 27. This is the argument GRZAN uses most often when handling detention disputes.

4. Practical recommendations

  • When handling port detention incidents, GRZAN’s first step is to require the other party to state in writing the article on which the detention is based and the examination reference number, and to verify whether the goods have actually entered the Article 26 examination procedure.
  • If early release is to be sought under Article 27, the notarised no-disposal undertaking text must be prepared in advance and its format confirmed with the receiving party. Practical estimate: undertakings issued abroad normally need to be provided in Arabic or in a bilingual Arabic-English version (no official provision found).
  • Confirm with the warehouse operator whether it can accept direct supervision by the competent authority and be sealed with red wax. Where an ordinary bonded warehouse cannot meet these conditions, an application under Article 27 will not be accepted in practice.
  • Tender documents and agency agreements should provide in advance who bears warehousing costs arising while awaiting examination, and whether the notarisation and supervision costs under Article 27 fall on the importer or the supplier.
  • Where payment demands are raised in the name of expediting fees or release coordination fees, GRZAN requires clients to ask for written Arabic legal authority and an official fiscal receipt in every case, and to refuse payment where neither is provided.

5. Verification checklist

  • □ Check the current wording of the two key expressions in Article 27 of the gazette full text: the notary and the red wax.
  • □ Confirm whether the successive amendments (Nos. 53 / 71 / 54 / 20) touch Article 27.
  • □ Obtain from the local customs broker sample documents for early release, including the undertaking template and the name of the authority accepting the notarisation.
  • □ Verify whether the warehouse intended for use is recognised by the competent authority as a premises acceptable for storage under official supervision.
  • □ Search in Arabic for later Ministry of Health instructions and confirm whether sealing and undertaking operations have been further detailed.
  • □ Re-check whether the official documents cited in this article have been replaced by later directives or resolutions (verification baseline of this article: 29 October 2026).

Regulatory information verified to 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Iraqi market. Our team manages adverse event reporting and recall coordination, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail